Diamyd Medical’s rhGAD65 manufacturing facility on track for Diamyd® vaccine production

Small-scale experimental production of the recombinant human protein GAD65, the active component in the therapeutic diabetes vaccine Diamyd[®], is now established at the manufacturing facility in Umeå. Large-scale production is being set up primarily using Cytiva equipment. The future CGMP certified production process at the facility is a key part of Diamyd Medical’s regulatory strategy for potential future conditional and accelerated market approvals.“Our Umeå site has, despite an ongoing pandemic, in a short time been able to transfer the manufacturing technology to Diamyd Medical,” says